First Tracks Biotherapeutics, Inc. quarterly report, Q1 FY2026

Business Context and Reporting Period

Company: First Tracks Biotherapeutics, Inc. (TRAX)
Reporting Period: Quarter ended March 31, 2026
Status: Clinical-stage biotechnology company focused on autoimmune and inflammatory diseases. The financial statements are presented on a combined basis derived from former parent AnaptysBio, Inc., as the company was not a separate legal entity during the period. The Spin-Off from AnaptysBio was completed on April 20, 2026.

Key Financial Metrics

Metric (in thousands) Q1 2026 Q1 2025
Revenue $0 $0
Net Loss $(50,484) $(47,196)
Operating Expenses $52,811 $51,280
Research & Development (R&D) $33,955 $41,465
General & Administrative (G&A) $18,856 $9,815
Interest Income $2,328 $4,091
Cash and Cash Equivalents (End of Period) $248,469 $98,637
Short-term Investments $37,986 $73,442
Total Assets $290,576 $330,545
Net Cash Used in Operating Activities $(32,561) $(45,006)

Note: The company has no operating revenue. Expenses include significant allocations from AnaptysBio, Inc. Stock-based compensation expense was $11.5 million for Q1 2026.

Material Changes vs. Prior Period

  • Net Loss Increase: Net loss increased by approximately $3.3 million (7%) compared to Q1 2025, driven primarily by higher G&A expenses.
  • R&D Decrease: R&D expenses decreased by $7.5 million (18%). This was primarily due to an $8.4 million decrease in clinical expenses, specifically a $10.4 million reduction in external costs for the rosnilimab program, partially offset by a $5.5 million increase in external costs for the ANB033 program.
  • G&A Increase: G&A expenses increased by $9.0 million (92%). The increase was driven by a $3.6 million rise in stock-based compensation, a $3.8 million increase in legal expenses, and higher personnel costs.
  • Liquidity Position: Cash and cash equivalents increased by $150 million compared to the prior year period, reflecting the accumulation of capital prior to the Spin-Off. Short-term investments decreased by $35.5 million due to sales and maturities.

Outlook, Risks, and Unusual Items

  • Spin-Off and Private Placement: On April 20, 2026, the company completed its Spin-Off from AnaptysBio. Concurrently, it completed a private placement raising approximately $80 million gross proceeds from the sale of 5.8 million shares at $13.81 per share. Additionally, $100 million in cash was allocated from AnaptysBio on the distribution date.
  • Liquidity Outlook: Management believes existing cash, cash equivalents, and investments will fund operations for at least the next 12 months. The company expects to incur significant operating losses for the foreseeable future.
  • Clinical Pipeline Updates:
    • Rosnilimab: Completed an End-of-Phase 2 meeting with the FDA in Q1 2026. Phase 2b data in rheumatoid arthritis showed statistical significance in primary and secondary endpoints.
    • ANB033: Phase 1b trials are ongoing for celiac disease and eosinophilic esophagitis.
    • ANB101: Phase 1 trial in healthy volunteers is ongoing.
  • Risks: Key risks include the high failure rate of clinical trials, dependence on third-party manufacturers, potential inability to secure additional financing, and the challenges of operating as a standalone public company for the first time. The company is an "emerging growth company" and "smaller reporting company."

Investor Verification Checklist

  • Standalone Cost Structure: Verify the actual standalone cost structure post-Spin-Off, as historical financials include allocated costs from AnaptysBio that may not reflect future standalone expenses.
  • Cash Runway: Confirm the burn rate and cash runway following the April 2026 Spin-Off and Private Placement, specifically the utilization of the $100 million allocation and $80 million private placement proceeds.
  • Rosnilimab Phase 3: Monitor the timeline and design of Phase 3 trials for rosnilimab following the successful End-of-Phase 2 FDA meeting.
  • Transition Services: Review the terms of the Transition Services Agreement with AnaptysBio to understand ongoing cost dependencies and potential revenue from services provided to the former parent.
  • Intellectual Property: Assess the status of patent portfolios for ANB033, rosnilimab, and ANB101, particularly regarding the separation of IP rights from AnaptysBio.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.